GBP-1 acts as a tumor suppressor in colorectal cancer cells

Carcinogenesis

Volumn 34, Issue 1, 2013, Pages 153-162

  Britzen Laurent, Nathalie ^a   Lipnik, Karoline ^b   Ocker, Matthias ^c   Naschberger, Elisabeth ^a   Schellerer, Vera S ^a   Croner, Roland S ^a   Vieth, Michael ^d   Waldner, Maximilian ^a   Steinberg, Pablo ^e   Hohenadl, Christine ^b   Stürzl, Michael ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

^d Clinical Center Bayreuth   (Germany)

^e UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GUANYLATE BINDING PROTEIN 1; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL TRANSFORMATION; COLON MUCOSA; COLORECTAL CANCER; CONTROLLED STUDY; DOWN REGULATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; STROMA CELL;

ANIMALS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; GENES, TUMOR SUPPRESSOR; GTP-BINDING PROTEINS; HUMANS; MICE; RNA INTERFERENCE;

EID: 84872163979     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs310     Document Type: Article

References (59)

1. Ferlay,J. et al. (2007) Estimates of the cancer incidence and mortality in Europe in 2006. Ann. Oncol., 18, 581-592.
2. Vogelstein,B. et al. (1988) Genetic alterations during colorectal-tumor development. N. Engl. J. Med., 319, 525-532.
3. Peddareddigari,V.G. et al. (2010) The tumor microenvironment in colorectal carcinogenesis. Cancer Microenviron., 3, 149-166.
4. Ogino,S. et al. (2011) Cancer immunology-analysis of host and tumor factors for personalized medicine. Nat. Rev. Clin. Oncol., 8, 711-719.
5. Mlecnik,B. et al. (2011) Tumor immunosurveillance in human cancers. Cancer Metastasis Rev., 30, 5-12.
6. Fridman,W.H. et al. (2012) The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer, 12, 298-306.
7. Galon,J. et al. (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science, 313, 1960-1964.
8. Camus,M. et al. (2009) Coordination of intratumoral immune reaction and human colorectal cancer recurrence. Cancer Res., 69, 2685-2693.
9. Tosolini,M. et al. (2011) Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res., 71, 1263-1271.
10. Nosho,K. et al. (2010) Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J. Pathol., 222, 350-366.
11. Ong,S.M. et al. (2012) Macrophages in human colorectal cancer are proinflammatory and prime T cells towards an anti-tumour type-1 inflammatory response. Eur. J. Immunol., 42, 89-100.
12. Dunn,G.P. et al. (2006) Interferons, immunity and cancer immunoediting. Nat. Rev. Immunol., 6, 836-848.
13. Zhu,J. et al. (2010) Heterogeneity and plasticity of T helper cells. Cell Res., 20, 4-12.
14. Kaplan,D.H. et al. (1998) Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc. Natl. Acad. Sci. U.S.A., 95, 7556-7561.
15. Street,S.E. et al. (2002) Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J. Exp. Med., 196, 129-134.
16. Enzler,T. et al. (2003) Deficiencies of GM-CSF and interferon gamma link inflammation and cancer. J. Exp. Med., 197, 1213-1219.
17. Gao,Y. et al. (2003) Gamma delta T cells provide an early source of interferon gamma in tumor immunity. J. Exp. Med., 198, 433-442.
18. Dunn,G.P. et al. (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol., 3, 991-998.
19. Schreiber,R.D. et al. (2011) Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science, 331, 1565-1570.
20. Naschberger,E. et al. (2008) Angiostatic immune reaction in colorectal carcinoma: Impact on survival and perspectives for antiangiogenic therapy. Int. J. Cancer, 123, 2120-2129.
21. Cheng,Y.S. et al. (1983) Interferon induction of fibroblast proteins with guanylate binding activity. J. Biol. Chem., 258, 7746-7750.
22. Lubeseder-Martellato,C. et al. (2002) Guanylate-binding protein-1 expression is selectively induced by inflammatory cytokines and is an activation marker of endothelial cells during inflammatory diseases. Am. J. Pathol., 161, 1749-1759.
23. Naschberger,E. et al. (2006) Human guanylate binding protein-1 is a secreted GTPase present in increased concentrations in the cerebrospinal fluid of patients with bacterial meningitis. Am. J. Pathol., 169, 1088-1099.
24. Praefcke,G.J. et al. (2004) The dynamin superfamily: universal membrane tubulation and fission molecules? Nat. Rev. Mol. Cell Biol., 5, 133-147.
25. Martens,S. et al. (2006) The interferon-inducible GTPases. Annu. Rev. Cell Dev. Biol., 22, 559-589.
26. Ghosh,A. et al. (2006) How guanylate-binding proteins achieve assemblystimulated processive cleavage of GTP to GMP. Nature, 440, 101-104.
27. Vöpel,T. et al. (2010) Mechanism of GTPase-activity-induced self-assembly of human guanylate binding protein 1. J. Mol. Biol., 400, 63-70.
28. Britzen-Laurent,N. et al. (2010) Intracellular trafficking of guanylate-binding proteins is regulated by heterodimerization in a hierarchical manner. PLoS ONE, 5, e14246.
29. Wehner,M. et al. (2012) The guanine cap of human guanylate-binding protein 1 is responsible for dimerization and self-activation of GTP hydrolysis. FEBS J., 279, 203-210.
30. Anderson,S.L. et al. (1999) Interferon-induced guanylate binding protein-1 (GBP-1) mediates an antiviral effect against vesicular stomatitis virus and encephalomyocarditis virus. Virology, 256, 8-14.
31. Itsui,Y. et al. (2009) Antiviral effects of the interferon-induced protein guanylate binding protein 1 and its interaction with the hepatitis C virus NS5B protein. Hepatology, 50, 1727-1737.
32. Tietzel,I. et al. (2009) Human guanylate binding proteins potentiate the anti-chlamydia effects of interferon-gamma. PLoS ONE, 4, e6499.
33. Guenzi,E. et al. (2001) The helical domain of GBP-1 mediates the inhibition of endothelial cell proliferation by inflammatory cytokines. EMBO J., 20, 5568-5577.
34. Guenzi,E. et al. (2003) The guanylate binding protein-1 GTPase controls the invasive and angiogenic capability of endothelial cells through inhibition of MMP-1 expression. EMBO J., 22, 3772-3782.
35. Weinländer,K. et al. (2008) Guanylate binding protein-1 inhibits spreading and migration of endothelial cells through induction of integrin alpha4 expression. FASEB J., 22, 4168-4178.
36. Cancer Genome Atlas Network (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature, 487, 330-337.
37. Herbst,U. et al. (2006) Malignant transformation of human colon epithelial cells by benzo[c]phenanthrene dihydrodiolepoxides as well as 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Toxicol. Appl. Pharmacol., 212, 136-145.
38. Kuhn,E. et al. (2012) A novel chip-based parallel transfection assay to evaluate paracrine cell interactions. Lab Chip, 12, 1363-1372.
39. Harvat,B.L. et al. (1996) Gamma-interferon induces an irreversible growth arrest in mid-G1 in mammary epithelial cells which correlates with a block in hyperphosphorylation of retinoblastoma. Cell Growth Differ., 7, 289-300.
40. Pfizenmaier,K. et al. (1985) Differential gamma-interferon response of human colon carcinoma cells: inhibition of proliferation and modulation of immunogenicity as independent effects of gamma-interferon on tumor cell growth. Cancer Res., 45, 3503-3509.
41. Hiroi,M. et al. (2009) Mechanisms of resistance to interferon-gammamediated cell growth arrest in human oral squamous carcinoma cells. J. Biol. Chem., 284, 24869-24880.
42. Kortylewski,M. et al. (2004) Interferon-gamma-mediated growth regulation of melanoma cells: involvement of STAT1-dependent and STAT1-independent signals. J. Invest. Dermatol., 122, 414-422.
43. Li,M. et al. (2011) Guanylate binding protein 1 is a novel effector of EGFR-driven invasion in glioblastoma. J. Exp. Med., 208, 2657-2673.
44. Yu,C.J. et al. (2011) Identification of guanylate-binding protein 1 as a potential oral cancer marker involved in cell invasion using omics-based analysis. J. Proteome Res., 10, 3778-3788.
45. Clemens,M.J. (2003) Interferons and apoptosis. J. Interferon Cytokine Res., 23, 277-292.
46. Pammer,J. et al. (2006) Interferon-alpha prevents apoptosis of endothelial cells after short-term exposure but induces replicative senescence after continuous stimulation. Lab. Invest., 86, 997-1007.
47. Reiman,J.M. et al. (2007) Tumor immunoediting and immunosculpting pathways to cancer progression. Semin. Cancer Biol., 17, 275-287.
48. Schnoor,M. et al. (2009) Guanylate-binding protein-1 is expressed at tight junctions of intestinal epithelial cells in response to interferon-gamma and regulates barrier function through effects on apoptosis. Mucosal Immunol., 2, 33-42.
49. Dunn,G.P. et al. (2005) IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression. Cancer Res., 65, 3447-3453.
50. Rodríguez,T. et al. (2007) Distinct mechanisms of loss of IFN-gamma mediated HLA class I inducibility in two melanoma cell lines. BMC Cancer, 7, 34.
51. Xi,S. et al. (2006) Decreased STAT1 expression by promoter methylation in squamous cell carcinogenesis. J. Natl. Cancer Inst., 98, 181-189.
52. Respa,A. et al. (2011) Association of IFN-gamma signal transduction defects with impaired HLA class I antigen processing in melanoma cell lines. Clin. Cancer Res., 17, 2668-2678.
53. Saha,B. et al. (2010) Gene modulation and immunoregulatory roles of interferon gamma. Cytokine, 50, 1-14.
54. Lipnik,K. et al. (2010) Interferon gamma-induced human guanylate binding protein 1 inhibits mammary tumor growth in mice. Mol. Med., 16, 177-187.
55. Carretero,R. et al. (2012) Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes. Int. J. Cancer, 131, 387-395.
56. Ascierto,M.L. et al. (2012) A signature of immune function genes associated with recurrence-free survival in breast cancer patients. Breast Cancer Res. Treat., 131, 871-880.
57. Naschberger,E. et al. (2011) Increased expression of guanylate binding protein-1 in lesional skin of patients with cutaneous lupus erythematosus. Exp. Dermatol., 20, 102-106.
58. Ascierto,M.L. et al. (2011) An immunologic portrait of cancer. J. Transl. Med., 9, 146.
59. Wang,E. et al. (2008) The immunologic constant of rejection. Trends Immunol., 29, 256-262.